<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; OSIR</title>
	<atom:link href="http://www.stockbloghub.com/tag/osir/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ASTM) Aastrom Biosciences Analyst Initiates Coverage at Neutral</title>
		<link>http://www.stockbloghub.com/2010/07/30/astm-aastrom-biosciences-analyst-initiates-coverage-at-neutral/45258</link>
		<comments>http://www.stockbloghub.com/2010/07/30/astm-aastrom-biosciences-analyst-initiates-coverage-at-neutral/45258#comments</comments>
		<pubDate>Fri, 30 Jul 2010 14:32:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Aastrom Biosciences Inc]]></category>
		<category><![CDATA[ASTM]]></category>
		<category><![CDATA[CLI]]></category>
		<category><![CDATA[Cytori Therapeutics Inc]]></category>
		<category><![CDATA[CYTX]]></category>
		<category><![CDATA[NTT DoCoMo]]></category>
		<category><![CDATA[OSIR]]></category>
		<category><![CDATA[Osiris Therapeutics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45258</guid>
		<description><![CDATA[We are initiating coverage of Aastrom Biosciences (ASTM) with a Neutral rating and $2.50 price target. Aastrom is pioneering the research effort on adult stem cells for therapeutic applications, specifically for the treatment of cardiovascular diseases such as critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). Aastrom’s approach involves expansion of a patient’s own stem and progenitor cells outside of the body to generate a cell product with significantly increased numbers of highly functional early-stage cells. These autologous cell products can then be used for the repair or regeneration of multiple human tissues. The company has developed a proprietary Tissue Repair Cell technology in which cells are derived from a small amount of bone marrow taken from a patient and expanded in culture to generate a unique cell mixture containing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/30/astm-aastrom-biosciences-analyst-initiates-coverage-at-neutral/45258/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OSIR) Osiris Therapeutics Misses Estimates</title>
		<link>http://www.stockbloghub.com/2010/03/03/osir-osiris-therapeutics-misses-estimates/29549</link>
		<comments>http://www.stockbloghub.com/2010/03/03/osir-osiris-therapeutics-misses-estimates/29549#comments</comments>
		<pubDate>Wed, 03 Mar 2010 23:02:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[OSIR]]></category>
		<category><![CDATA[Osiris Therapeutics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29549</guid>
		<description><![CDATA[Osiris Therapeutics (OSIR) reported a net loss of a cent in the fourth quarter of 2009, well below the Zacks Consensus Estimate of a net income of 23 cents per share. However, net loss in the year ago period was higher at 37 cents, mainly due to lower revenues and higher clinical trial expenses. Revenues in the reported quarter increased to $10.8 million compared to $6.2 million for the same period of the prior year. Osiris generates revenues from collaborative agreements, research licenses, and government contracts. For 2009, the company reported a loss of 72 cents, well below the loss of $2.18 reported in 2008. Revenues jumped to $44.5 million, significantly above $10 million reported in 2008. Revenues in the reported quarter included the recognition of $10 million in revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/osir-osiris-therapeutics-misses-estimates/29549/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OSIR) Osiris Therapeutics Posts Loss</title>
		<link>http://www.stockbloghub.com/2009/11/14/osir-osiris-therapeutics-posts-loss/20432</link>
		<comments>http://www.stockbloghub.com/2009/11/14/osir-osiris-therapeutics-posts-loss/20432#comments</comments>
		<pubDate>Sun, 15 Nov 2009 00:13:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[OSIR]]></category>
		<category><![CDATA[Osiris Therapeutics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20432</guid>
		<description><![CDATA[Osiris Therapeutics (OSIR) reported a net loss of 21 cents per share in the third quarter of 2009, well above the Zacks Consensus Estimate of a net income of 6 cents. However, net loss in the year ago period was higher at 63 cents, mainly due to lower revenues. Revenues in the reported quarter increased to $10.6 million compared to $0.995 million for the same period of the prior year. Osiris generates revenues from collaborative agreements, research licenses, and government contracts. Revenues in the reported quarter included the recognition of $10 million in revenue under the company’s agreement with Genzyme Corporation (GENZ) for the development and commercialization of Prochymal and Chondrogen. Osiris earned $0.4 million from its collaborative agreement with the Juvenile Diabetes Research Foundation (JDRF) for the development of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/osir-osiris-therapeutics-posts-loss/20432/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(OSIR) Osiris Therapeutics’ Prochymal Found Ineffective</title>
		<link>http://www.stockbloghub.com/2009/09/09/osir-osiris-therapeutics%e2%80%99-prochymal-found-ineffective/14724</link>
		<comments>http://www.stockbloghub.com/2009/09/09/osir-osiris-therapeutics%e2%80%99-prochymal-found-ineffective/14724#comments</comments>
		<pubDate>Wed, 09 Sep 2009 22:12:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[OSIR]]></category>
		<category><![CDATA[Osiris Therapeutics Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14724</guid>
		<description><![CDATA[We are disappointed with the failure of Osiris Therapeutics’ (OSIR) Prochymal, a drug derived from human stem cell for the treatment of graft-versus-host disease (GvHD), the most common complication of bone marrow transplants. Currently, there is no approved treatment available for this life-threatening disease. Based on the preliminary results of two phase III trials conducted by the company, Prochymal was found to be ineffective compared to placebo. Following the setback, Osiris shares fell by 34% to $8.03, their greatest single day decline since August 2006. In the first trial, where the drug was used along with steroids, 45% of patients responded to the combination compared to 46% who responded to steroid along with a placebo. In the second trial, when Prochymal was used on patients not benefiting from steroids, it ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/09/osir-osiris-therapeutics%e2%80%99-prochymal-found-ineffective/14724/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

